ASCPT News

ASCPT News
Published: (2024)

ASCPT News
Published: (2024)

ASCPT News
Published: (2025)

ASCPT News
Published: (2024)

ASCPT News
Published: (2024)

ASCPT News
Published: (2024)

ASCPT News
Published: (2025)

ASCPT News
Published: (2025)

ASCPT News
Published: (2024)

ASCPT News
Published: (2025)

ASCPT News
Published: (2025)

ASCPT News
Published: (2025)

ASCPT News
Published: (2024)

ASCPT News
Published: (2025)

ASCPT News
Published: (2025)

ASCPT 125th Anniversary: A Society Leadership Perspective
by: Matthew L. Rizk, et al.
Published: (2025)

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network
by: Priya Jayachandran, et al.
Published: (2026)

Attaining Equity of Access to Research: Perspective on Research in Pregnancy and Breastfeeding Following Dolores Shockley Lecture at ASCPT2024
by: Catriona Waitt, et al.
Published: (2024)

Effect of Target‐Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function
by: Elise Burmeister Getz, et al.
Published: (2025)

Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs
by: Wei Gao, et al.
Published: (2025)

Impact of Antihypertensive Treatment on Outcomes of Adjuvant Bevacizumab for Ovarian Cancer ( IATRO ), Results from a Nationwide Emulated Clinical Trial
by: Floriane Jochum, et al.
Published: (2025)

Use of FDA Expedited Programs and Development Timelines for New Molecular Entity Drug and New Biologic Approvals by Sponsor Experience
by: Kanhai S. Amin, et al.
Published: (2025)

Promise of Quantitative Proteomics in the Qualification of New Approach Methodologies
by: Bhagwat Prasad
Published: (2025)

Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals
by: Noah C. Neverette, et al.
Published: (2024)

Best Practices for Pharmacokinetic Studies of New Chemical Entities
by: Ya‐Feng Wen, et al.
Published: (2024)

Correction to “Promise of Quantitative Proteomics in the Qualification of New Approach Methodologies”
Published: (2026)

BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase
by: Aurélie Cabannes‐Hamy, et al.
Published: (2025)

Artificial Intelligence/Machine Learning: The New Frontier of Clinical Pharmacology and Precision Medicine
by: Qi Liu, et al.
Published: (2024)

New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
by: Amitava Mitra, et al.
Published: (2024)

Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins
by: Yow‐Ming C. Wang, et al.
Published: (2024)

New Horizons for Clinical Pharmacology & Therapeutics : Global Outreach for Optimal Patient Outcomes
by: Karen Rowland Yeo
Published: (2025)

A Comparison of Regional Decisions for Doses and Administrations of New Drugs: Concordance, Discordance, and Dependencies
by: Sachiko Mita, et al.
Published: (2026)

Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs
by: Miquel Serra‐Burriel, et al.
Published: (2026)

The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug Modalities
by: Matthew M. Abernathy, et al.
Published: (2024)

Current Use of Physiologically Based Pharmacokinetic modeling in New Medicinal Product Approvals at EMA
by: Polly Paul, et al.
Published: (2025)

From Classical PKPD to Model‐Informed Drug Development: Are “Digital Twins” a New Paradigm?
by: Brett E. Houk
Published: (2026)